Anthropometric indices of central obesity how discriminators of metabolic syndrome in Brazilian women with polycystic ovary syndrome

2011 ◽  
Vol 28 (1) ◽  
pp. 12-15 ◽  
Author(s):  
Eduardo Caldas Costa ◽  
Joceline Cássia Ferezini de Sá ◽  
Elvira Maria Mafaldo Soares ◽  
Telma Maria Araújo Moura Lemos ◽  
Técia Maria de Oliveira Maranhão ◽  
...  
2021 ◽  
Vol 39 (4) ◽  
pp. 225-232
Author(s):  
Shakeela Ishrat ◽  
Marufa Hussain

Introduction: Polycystic ovary syndrome (PCOS) affects 5-10% of reproductive age women and it is a common cause of infertility in young women. Most of the infertile women with PCOS are overweight or obese with related risks of insulin resistance, dyslipidemia and metabolic syndrome. There is ethnic variation in the prevalence of obesity and its related metabolic abnormalities in women with polycystic ovary syndrome. This study was designed to explore the prevalence of insulin resistance, dyslipidemia and metabolic syndrome in infertile women with polycystic ovary syndrome in Bangladesh. Methods: This was a cross sectional study of 126 infertile women with polycystic ovary syndrome attending the Infertility unit of the Department of Obstertrics and Gynaecology at Bangabandhu Sheikh Mujib Medical University from January 2017 to December 2017. Results: The mean BMI was 26.58±3.18 and mean waist circumference was 91.07±9.5 cm. Regarding the prevalence of obesity, 47.6% of the women were overweight (BMI 23 - 27.5 kg/m2), 39.7% was obese (BMI>27.5 kg/m2) and central obesity (waist circumference ≥80 cm) was in 80.2%. In infertile women of PCOS, the prevalence of insulin resistance was 27.8% , dyslipidemia 93.7% metabolic syndrome 42.9% .Median fasting insulin was higher than the cut off for insulin resistance specific for south Asian population. Insulin resistance measured by hyperinsulinemia was much more frequent (65.9%) than that measured by HOMA-IR (27.8%).The most common lipid abnormality was low HDL cholesterol (90.5%) followed by elevated LDL-cholesterol (79.4%). Low HDL cholesterol (90.5%) and abdominal or central obesity (80.2%) were the most common criteria of metabolic syndrome. There is increasing trend in metabolic syndrome with age. Conclusion: Screening the infertile women with polycystic ovary syndrome for insulin resistance, dyslipidemia and metabolic syndrome is important because it allows for additional counseling about long term health consequences and emphasis on weight management. J Bangladesh Coll Phys Surg 2021; 39: 225-232


2013 ◽  
Author(s):  
Antic Ivana Bozic ◽  
Jelica Bjekic-Macut ◽  
Dimitrios Panidis ◽  
Danijela Vojnovic Milutinovic ◽  
Biljana Kastratovic ◽  
...  

2014 ◽  
Author(s):  
Ivana Bozic Antic ◽  
Djuro Macut ◽  
Jelica Bjekic-Macut ◽  
Danijela Vojnovic Milutinovic ◽  
Milan Petakov ◽  
...  

2019 ◽  
Vol 17 (6) ◽  
pp. 595-603 ◽  
Author(s):  
Sezcan Mumusoglu ◽  
Bulent Okan Yildiz

The metabolic syndrome (MetS) comprises individual components including central obesity, insulin resistance, dyslipidaemia and hypertension and it is associated with an increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The menopause per se increases the incidence of MetS in aging women. The effect(s) of menopause on individual components of MetS include: i) increasing central obesity with changes in the fat tissue distribution, ii) potential increase in insulin resistance, iii) changes in serum lipid concentrations, which seem to be associated with increasing weight rather than menopause itself, and, iv) an association between menopause and hypertension, although available data are inconclusive. With regard to the consequences of MetS during menopause, there is no consistent data supporting a causal relationship between menopause and CVD. However, concomitant MetS during menopause appears to increase the risk of CVD. Furthermore, despite the data supporting the association between early menopause and increased risk of T2DM, the association between natural menopause itself and risk of T2DM is not evident. However, the presence and the severity of MetS appears to be associated with an increased risk of T2DM. Although the mechanism is not clear, surgical menopause is strongly linked with a higher incidence of MetS. Interestingly, women with polycystic ovary syndrome (PCOS) have an increased risk of MetS during their reproductive years; however, with menopausal transition, the risk of MetS becomes similar to that of non-PCOS women.


2011 ◽  
Vol 96 (5) ◽  
pp. 1271-1274 ◽  
Author(s):  
Miriam Hudecova ◽  
Jan Holte ◽  
Matts Olovsson ◽  
Anders Larsson ◽  
Christian Berne ◽  
...  

Circulation ◽  
2021 ◽  
Vol 143 (Suppl_1) ◽  
Author(s):  
Hridya C Rao ◽  
Lindsay Fernandez-Rhodes ◽  
Michelle Meyer ◽  
Michelle Kominiarek ◽  
Linda Gallo ◽  
...  

Introduction: Polycystic Ovary Syndrome (PCOS) is associated with increased Metabolic Syndrome (MetS), however, these findings have not been characterized in Hispanic/Latina women who are disproportionately burdened by obesity and cardiovascular disease risk compared to non-Hispanic whites. It is also unclear if this association is moderated by elevated high-sensitivity C-Reactive Protein (hs-CRP) levels, a marker for inflammation and a predictor of cardiovascular disease. Hypothesis: In Hispanic/Latina women, we hypothesized that 1) PCOS (self-reported diagnosis and signs) is associated with a higher prevalence of MetS compared to those not reporting PCOS 2) elevated hs-CRP is associated with MetS, and 3) the PCOS-MetS association is moderated by elevated hs-CRP. Methods: We used information from reproductive and economic questionnaires and venous blood measurements collected in Hispanic Community Health Study/Study of Latinos (2008-2017), a U.S. community-based cohort study of Hispanic/Latino adults. PCOS was operationalized as either 1) signs of PCOS (e.g., menstrual cycles >35 days, irregular cycles (at age 20 to 40 years old when not using birth control pills or other hormone medications and not pregnant or breastfeeding) or 2) having answered “yes” to a self-reported question on PCOS. MetS was operationalized as ≥3 elevated subcomponents of MetS (i.e., waist circumference, hypertension, insulin resistance, lipid profile, and triglycerides). A hs-CRP value ≥3.0 mg/L was considered elevated. We adjusted for the complex survey study design, age, study center, Hispanic/Latina background, and age at immigration in all models. Results: The overall (unweighted N=9582) age ranged from 18 to 76 years (mean=41.74, SD=14.18). The prevalence of PCOS (self-reported diagnosis and signs) was 12% (1008/7366), prevalence of MetS was 40% (2380/3495), prevalence of elevated-hsCRP was 44% (3704/4667). PCOS was associated with a significantly higher odds of MetS before (OR 1.35, 95% CI: 1.06-1.71) and after adjusting for elevated-hsCRP (OR 1.29, 95%CI: 1.02-1.65). Elevated hs-CRP is significantly associated with MetS (OR 2.31, 95%CI: 1.95-2.76). There was no significant interaction effect of hs-CRP in the PCOS-MetS association. Conclusions: Prevalence of PCOS (self-reported and signs) was 12% in our sample of Hispanic/Latina women, which is consistent with the previous findings in non-Hispanic whites. Both PCOS (self-reported diagnosis and signs) and elevated hs-CRP were significantly associated with higher prevalence of MetS and could indicate women at metabolic disease risk.


Author(s):  
Anne-Marie Carreau ◽  
Marie-Hélène Pesant ◽  
Jean-Patrice Baillargeon

Sign in / Sign up

Export Citation Format

Share Document